Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 12691662 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Gong X, et al. (2003) Cdk5-mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis. Neuron 38, 33-46 12691662
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S408-p - MEF2A (human) ▲
Orthologous residues
MEF2A (human): S408‑p, MEF2A iso2 (human): S406‑p, MEF2A (mouse): S406‑p, MEF2A iso3 (mouse): S400‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phosphopeptide mapping
 Relevant cell lines - cell types - tissues:  'neuron, cortical'-brain, 293 (epithelial)
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  human, rat
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CDK5 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK5 (human) transfection of dominant-negative enzyme, transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
H2O2 increase
roscovitine H2O2 inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (process):  transcription, altered

S430-p - MEF2D (rat) ▲
Orthologous residues
MEF2D (human): S444‑p, MEF2D (mouse): S437‑p, MEF2D iso2 (mouse): S437‑p, MEF2D (rat): S430‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, phosphopeptide mapping, western blotting
 Relevant cell lines - cell types - tissues:  'neuron, cortical'-brain, 293 (epithelial)
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  human, rat
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CDK5 (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
glutamate increase
roscovitine glutamate inhibit treatment-induced increase
H2O2 increase
roscovitine H2O2 augment treatment-induced increase
Downstream Regulation
 Effect of modification (process):  apoptosis, induced


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.